RxDoctor Payments Data

Jeff Barone

Family · Tucson, AZNPI 1851620231

Payments from drug & device makers

$1,959in general payments, 2019–2025

Across 95 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$231
  • Novo Nordisk$212
  • Amgen$204
  • Abbott$182
  • Exact Sciences$170
  • AbbVie$142
  • plus $820 from 20 others

What the payments were for

  • Food & beverage$1,959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,959 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$151,369
Medicare patients
300
Services billed
2,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$86,546
JardianceEmpagliflozin20$26,823
Breo ElliptaFluticasone/Vilanterol12$7,377
SavellaMilnacipran Hcl12$5,695
Spiriva RespimatTiotropium Bromide11$5,551
Rosuvastatin Calcium181$3,961
Gabapentin123$1,980
Levothyroxine Sodium212$1,581
Liothyronine Sodium28$1,435
Losartan Potassium132$1,377
Bupropion XlBupropion Hcl27$925
Omeprazole47$918
Atorvastatin Calcium141$866
Amlodipine Besylate140$858
Baclofen44$804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$212$86,54645 claims
Boehringer IngelheimJardiance, Spiriva Respimat$17$32,37431 claims
GSKBreo Ellipta$102$7,37712 claims
AbbVieSavella$142$5,69512 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$38$1,581212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →